智通财经网·2025-12-17 01:52Core Viewpoint - The stock of Zhaoyan New Drug (06127) has risen over 8%, currently trading at HKD 22.14, with a transaction volume of HKD 39.86 million, driven by increasing demand for experimental monkeys used in preclinical safety evaluations [1] Group 1: Market Dynamics - Recent reports indicate a significant increase in the price of experimental monkeys, reaching approximately HKD 140,000 each as of December 9, 2025, due to rising demand and limited supply [1] - According to a report from Founder Securities, the demand for experimental monkeys is expected to rise as preclinical CRO orders recover, while supply-side expansion remains challenging [1] - Some monkey breeding facilities have indicated that their production capacity is already booked until the first quarter of 2026, suggesting a sustained tight supply situation [1] Group 2: Financial Implications - Founder Securities estimates that the fair value of experimental monkeys could increase from an average of HKD 84,900 per monkey in 2024 to HKD 140,000 by Q4 2025, with a projected output rate of 17% from breeding facilities [1] - Based on the known quantity of 23,200 monkeys, the estimated additional fair value for 2025 could reach approximately HKD 220 million, not accounting for new additions or the impact of juvenile and aging monkeys [1]